文献速递胃肠动力与功能性疾病

临床医生与保险公司对肠易激综合征管理视角的差异:多水平模型分析

Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

结果显示,从商业保险公司视角,先使用全局IBS治疗(神经调节剂、低FODMAP饮食、认知行为疗法)再使用处方药,较直接起始处方药可节省费用且健康结局相似。

要点

  • 保险公司视角下,先全局治疗再处方药可节省费用且结局相似。
  • IBS-D最节省成本的算法为利福昔明→艾芦沙多→阿洛司琼。
  • IBS-C最节省成本的算法为利那洛肽→普卡那肽或鲁比前列酮。

核心结论

  • 从保险公司视角,常规和算法化处方药覆盖限制要求先失败于低成本行为、饮食和超说明书治疗,具有成本效果。

主要发现

  • 先使用全局IBS治疗再使用FDA批准药物,较直接起始标签内药物,IBS-D每患者1年节省9034.59美元,IBS-C节省2972.83美元。
  • 无论治疗顺序如何,健康结局相似;全局IBS治疗顺序不同,费用差异小于每年200美元。
  • IBS-D最节省成本且最具成本效果的算法为利福昔明、然后艾芦沙多、然后阿洛司琼。
  • IBS-C最节省成本且最具成本效果的算法为利那洛肽、然后普卡那肽或鲁比前列酮。
  • 没有任何场景中处方药常规比全局IBS治疗更具成本效果,尽管处方药证据等级更强; findings由处方药价格高于全局治疗驱动。

临床怎么用

  • 保险公司可考虑要求先失败于低成本行为、饮食和超说明书治疗后再覆盖处方药,以控制成本。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Insurance coverage is an important determinant of treatment choice in irritable bowel syndrome (IBS), often taking precedence over desired mechanisms of action or patient goals/values. We aimed to determine whether routine and algorithmic coverage restrictions are cost-effective from a commercial insurer perspective. METHODS: A multilevel microsimulation tracking costs and outcomes among 10 million hypothetical moderate-to-severe patients with IBS was developed to model all possible algorithms including common global IBS treatments (neuromodulators; low fermentable oligo-, di-, and mono-saccharides, and polyols; and cognitive behavioral therapy) and prescription drugs treating diarrhea-predominant IBS (IBS-D) or constipation-predominant IBS (IBS-C) over 1 year. RESULTS: Routinely using global IBS treatments (central neuromodulator; low fermentable oligo-, di-, and mono-saccharides, and polyols; and cognitive behavioral therapy) before US Food and Drug Administration-approved drug therapies resulted in per-patient cost savings of $9,034.59 for IBS-D and $2,972.83 for IBS-C over 1 year to insurers, compared with patients starting with on-label drug therapy. Health outcomes were similar, regardless of treatment sequence. Costs varied less than $200 per year, regardless of the global IBS treatment order. The most cost-saving and cost-effective IBS-D algorithm was rifaximin, then eluxadoline, followed by alosetron. The most cost-saving and cost-effective IBS-C algorithm was linaclotide, followed by either plecanatide or lubiprostone. In no scenario were prescription drugs routinely more cost-effective than global IBS treatments, despite a stronger level of evidence with prescription drugs. These findings were driven by higher prescription drug prices as compared to lower costs with global IBS treatments. DISCUSSION: From an insurer perspective, routine and algorithmic prescription drug coverage restrictions requiring failure of low-cost behavioral, dietary, and off-label treatments appear cost-effective. Efforts to address insurance coverage and drug pricing are needed so that healthcare providers can optimally care for patients with this common, heterogenous disorder.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shah ED, Chang L, Salwen-Deremer JK, et al. Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis. Am J Gastroenterol. 2021. PMID: 33982945. doi:10.14309/ajg.0000000000000989

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。